Avanos Medical Inc (AVNS) Reports Mixed 2023 Financial Results Amid Transformation Initiative
-
Net Sales: Full-year net sales from continuing operations decreased by 1.6% to $673.3 million.
-
Earnings Per Share: Diluted earnings per share from continuing operations for Q4 were $0.24, up from $0.21 year-over-year; full-year diluted loss per share was $0.21.
-
Free Cash Flow: 2023 full-year free cash flow was $14.6 million, a significant decrease from $71.6 million in 2022.
-
Adjusted EBITDA: Adjusted EBITDA for the full year increased to $98.9 million from $91.2 million in the previous year.
-
Strategic Moves: Completed the sale of the respiratory health business and acquired Diros Technology, Inc., enhancing pain management portfolio.
-
2024 Outlook: Expects net sales between $685 and $705 million with adjusted diluted earnings per share between $1.30 to $1.45.
On February 20, 2024, Avanos Medical Inc (NYSE:AVNS) released its 8-K filing, announcing its fourth quarter and full-year 2023 results. The company, known for its medical devices and services in pain management, IV therapy, and respiratory and digestive health, has been actively engaged in a transformation initiative aimed at optimizing its commercial organization, transforming its product portfolio, and enhancing operating profitability.
Company Overview
Avanos Medical Inc operates primarily in the medical devices sector, with a focus on non-opioid pain management and chronic care solutions. The company's Pain Management franchise offers products for acute and interventional pain, including cold and compression therapy, while its Chronic Care franchise addresses digestive and respiratory issues with feeding tubes and catheters. Avanos generates the majority of its revenue from the Chronic Care franchise and its operations in North America.
Performance and Challenges
The company's financial performance in 2023 reflects the challenges and strategic decisions made during the year. Net sales from continuing operations saw a slight decrease, attributed mainly to lower sales in the Pain Management and Recovery portfolio, particularly hyaluronic acid (HA) pain relief products. This was partially offset by strong demand for Digestive Health products and favorable foreign currency translation effects.
Despite the sales dip, Avanos achieved a modest increase in adjusted EBITDA and maintained a focus on strategic growth through the acquisition of Diros Technology, Inc., which is expected to enhance its Pain Management and Recovery offerings. The divestiture of the respiratory health business is also a significant step in streamlining the company's focus on its core competencies.